Displaying drugs 14426 - 14450 of 14871 in total
PD-0299685
PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).
Investigational
Matched Description: … Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With …
Hydroxypropyl betadex
Hydroxypropyl betadex is under investigation in clinical trial NCT03471143 (Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C).
Investigational
Matched Description: … investigation in clinical trial NCT03471143 (Study of IV VTS-270 for Infantile Liver Disease Associated With …
LB-100
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
Investigational
Matched Description: … LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or …
CXD101
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
Matched Description: … CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …
Seladelpar
Seladelpar (MBX-8025) has been used in trials studying the treatment of Hyperlipidemia.
Investigational
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. Known drug targets of (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and naphthalene 1,2-dioxygenase subunit alpha.
Experimental
Matched Description: … (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and …
Clocapramine
Clocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic. Clocapramine has been implicated in at least one strange death,...
Experimental
Matched Description: … to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and …
2,5-Dimethoxy-4-(n)-propylthiophenethylamine
Experimental
Illicit
Embutramide
Experimental
Illicit
4-Bromo-2,5-dimethoxyphenethylamine
Experimental
Illicit
SC-74020
Experimental
R048-8071
Experimental
N-Cyclohexyl-N'-(4-Iodophenyl)Urea
Experimental
N-Butyl-Benzenesulfonamide
Experimental
3,5-Difluorobenzenesulfonamide
Experimental
4-iodo-acetamido phenylboronic acid
Experimental
Displaying drugs 14426 - 14450 of 14871 in total